Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7070179 in Hepatocellular Carcinoma
NCT02564614Phase 1Completed
- Sponsor
- Roche
- Start
- May 2016
- Primary completion
- Jan 2018
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ezn-2968 in hepatocellular carcinoma (HCC), sponsored by Roche. Primary endpoint: Change From Baseline to Week 6 in HIF1A mRNA Level in Tumor Tissue. Started May 2016; status: completed.
02
Drugs
ezn-2968
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02564614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564614.